{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T03:23:05Z","timestamp":1784258585607,"version":"3.55.0"},"reference-count":90,"publisher":"Bentham Science Publishers Ltd.","issue":"4","funder":[{"DOI":"10.13039\/501100004320","name":"Shiraz University of Medical Sciences","doi-asserted-by":"publisher","award":["97-01-36-19208"],"award-info":[{"award-number":["97-01-36-19208"]}],"id":[{"id":"10.13039\/501100004320","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CDS"],"published-print":{"date-parts":[[2023,11]]},"abstract":"<jats:sec>\n<jats:title>Abstract:<\/jats:title>\n<jats:p>Vancomycin is considered the drug of choice against many Gram-positive bacterial infections.\nTherapeutic drug monitoring (TDM) is essential to achieve an optimum clinical response\nand avoid vancomycin-induced adverse reactions including nephrotoxicity. Although different\nstudies are available on vancomycin TDM, still there are controversies regarding the selection\namong different pharmacokinetic parameters including trough concentration, the area under the\ncurve to minimum inhibitory concentration ratio (AUC24h\/MIC), AUC of intervals, elimination\nconstant, and vancomycin clearance. In this review, different pharmacokinetic parameters for vancomycin\nTDM have been discussed along with corresponding advantages and disadvantages. Also,\nvancomycin pharmacokinetic assessments are discussed in patients with altered pharmacokinetic\nparameters including those with renal and\/or hepatic failure, critically ill patients, patients with\nburn injuries, intravenous drug users, obese and morbidly obese patients, those with cancer, patients\nundergoing organ transplantation, and vancomycin administration during pregnancy and lactation.\nAn individualized dosing regimen is required to guarantee the optimum therapeutic responses\nand minimize adverse reactions including acute kidney injury in these special groups of\npatients. According to the pharmacoeconomic data on vancomycin TDM, pharmacokinetic assessments\nwould be cost-effective in patients with altered pharmacokinetics and are associated with\nshorter hospitalization period, faster clinical stability status, and shorter courses of inpatient vancomycin\nadministration.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1574886317666220801124718","type":"journal-article","created":{"date-parts":[[2022,8,2]],"date-time":"2022-08-02T13:20:41Z","timestamp":1659446441000},"page":"425-439","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["A Brief Review of Pharmacokinetic Assessments of Vancomycin in Special\nGroups of Patients with Altered Pharmacokinetic Parameters"],"prefix":"10.2174","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8640-5724","authenticated-orcid":true,"given":"Parisa","family":"Ghasemiyeh","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran"},{"name":"Pharmaceutical Sciences Research Center, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Afsaneh","family":"Vazin","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1007-1422","authenticated-orcid":true,"given":"Soliman","family":"Mohammadi-Samani","sequence":"additional","affiliation":[{"name":"Pharmaceutical Sciences Research Center, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran"},{"name":"Department of Pharmaceutics, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","first-page":"163","volume":"11","author":"Vazin A.","year":"2012","unstructured":"Vazin A.; Japoni A.; Shahbazi S.; Davarpanah M.A.; Vancomycin utilization evaluation at hematology-oncology ward of a teaching hospital in Iran. Iran J Pharm Res 2012,11(1),163-170","journal-title":"Iran J Pharm Res"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1097\/FTD.0000000000000750","volume":"42","author":"Zhang Y.","year":"2020","unstructured":"Zhang Y.; Wang T.; Zhang D.; Therapeutic drug monitoring coupled with bayesian forecasting could prevent vancomycin-associated nephrotoxicity in renal insufficiency patients: A prospective study and pharmacoeconomic analysis. Ther Drug Monit 2020,42(4),600-609","journal-title":"Ther Drug Monit"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1007\/s13318-017-0456-4","volume":"43","author":"Elbarbry F.","year":"2018","unstructured":"Elbarbry F.; Vancomycin dosing and monitoring: Critical evaluation of the current practice. Eur J Drug Metab Pharmacokinet 2018,43(3),259-268","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1093\/jac\/dkf212","volume":"50","author":"Tobin C.M.","year":"2002","unstructured":"Tobin C.M.; Darville J.M.; Thomson A.H.; Vancomycin therapeutic drug monitoring: Is there a consensus view? The results of a UK National External Quality Assessment Scheme (UK NEQAS) for antibiotic assays questionnaire. J Antimicrob Chemother 2002,50(5),713-718","journal-title":"J Antimicrob Chemother"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1038\/ki.2010.35","volume":"77","author":"Vandecasteele S.J.","year":"2010","unstructured":"Vandecasteele S.J.; De Vriese A.S.; Recent changes in vancomycin use in renal failure. Kidney Int 2010,77(9),760-764","journal-title":"Kidney Int"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"529","DOI":"10.4103\/1735-5362.301337","volume":"15","author":"Ghasemiyeh P.","year":"2020","unstructured":"Ghasemiyeh P.; Vazin A.; Zand F.; Azadi A.; Karimzadeh I.; Mohammadi-Samani S.; A simple and validated HPLC method for vancomycin assay in plasma samples: The necessity of TDM center development in Southern Iran. Res Pharm Sci 2020,15(6),529-540","journal-title":"Res Pharm Sci"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"2365","DOI":"10.2146\/ajhp060047","volume":"63","author":"Murphy J.E.","year":"2006","unstructured":"Murphy J.E.; Gillespie D.E.; Bateman C.V.; Predictability of vancomycin trough concentrations using seven approaches for estimating pharmacokinetic parameters. Am J Health Syst Pharm 2006,63(23),2365-2370","journal-title":"Am J Health Syst Pharm"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1186\/2047-783X-15-12-533","volume":"15","author":"Estes K.S.","year":"2010","unstructured":"Estes K.S.; Derendorf H.; Comparison of the pharmacokinetic properties of vancomycin, linezolid, tigecyclin, and daptomycin. Eur J Med Res 2010,15(12),533-543","journal-title":"Eur J Med Res"},{"key":"ref=9","year":"2021","unstructured":"Drug information: Vancomycin. Available from: 2021"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1093\/jpids\/piz036","volume":"9","author":"Olson J.","year":"2020","unstructured":"Olson J.; Hersh A.L.; Sorensen J.; Zobell J.; Anderson C.; Thorell E.A.; Intravenous vancomycin therapeutic drug monitoring in children: Evaluation of a pharmacy-driven protocol and collaborative practice agreement. J Pediatric Infect Dis Soc 2020,9(3),334-341","journal-title":"J Pediatric Infect Dis Soc"},{"key":"ref=11","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1080\/1120009X.2020.1755590","volume":"33","author":"Kim S.H.","year":"2020","unstructured":"Kim S.H.; Kang C.I.; Lee S.H.; Choi J.S.; Huh K.; Cho S.Y.; Weight-based vancomycin loading strategy may not improve achievement of optimal vancomycin concentration in patients with preserved renal function. J Chemother 2020,33(1),56-61","journal-title":"J Chemother"},{"key":"ref=12","first-page":"379","volume":"69","author":"Gupta A.","year":"2011","unstructured":"Gupta A.; Biyani M.; Khaira A.; Vancomycin nephrotoxicity: Myths and facts. Neth J Med 2011,69(9),379-383","journal-title":"Neth J Med"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1177\/0897190014546114","volume":"27","author":"Mergenhagen K.A.","year":"2014","unstructured":"Mergenhagen K.A.; Borton A.R.; Vancomycin nephrotoxicity: A review. J Pharm Pract 2014,27(6),545-553","journal-title":"J Pharm Pract"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/j.jpeds.2010.08.019","volume":"158","author":"McKamy S.","year":"2011","unstructured":"McKamy S.; Hernandez E.; Jahng M.; Moriwaki T.; Deveikis A.; Le J.; Incidence and risk factors influencing the development of vancomycin nephrotoxicity in children. J Pediatr 2011,158(3),422-426","journal-title":"J Pediatr"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1093\/ajhp\/zxaa036","volume":"77","author":"Rybak M.J.","year":"2020","unstructured":"Rybak M.J.; Le J.; Lodise T.P.; Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: A revised consensus guideline and review by the American society of health-system pharmacists, the infectious diseases society of America, the pediatric infectious diseases society, and the society of infectious diseases pharmacists. Am J Health Syst Pharm 2020,77(11),835-864","journal-title":"Am J Health Syst Pharm"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1007\/s00134-020-06050-1","volume":"46","author":"Abdul-Aziz M.H.","year":"2020","unstructured":"Abdul-Aziz M.H.; Alffenaar J.C.; Bassetti M.; Antimicrobial therapeutic drug monitoring in critically ill adult patients: A position paper. Intensive Care Med 2020,46(6),1127-1153","journal-title":"Intensive Care Med"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1128\/AAC.01653-13","volume":"58","author":"Neely M.N.","year":"2014","unstructured":"Neely M.N.; Youn G.; Jones B.; Are vancomycin trough concentrations adequate for optimal dosing? Antimicrob Agents Chemother 2014,58(1),309-316","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1093\/cid\/cir078","volume":"52","author":"Patel N.","year":"2011","unstructured":"Patel N.; Pai M.P.; Rodvold K.A.; Lomaestro B.; Drusano G.L.; Lodise T.P.; Vancomycin: We can\u2019t get there from here. Clin Infect Dis 2011,52(8),969-974","journal-title":"Clin Infect Dis"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.ijantimicag.2015.10.019","volume":"47","author":"Hao J.J.","year":"2016","unstructured":"Hao J.J.; Chen H.; Zhou J.X.; Continuous versus intermittent infusion of vancomycin in adult patients: A systematic review and meta-analysis. Int J Antimicrob Agents 2016,47(1),28-35","journal-title":"Int J Antimicrob Agents"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/j.ijantimicag.2013.01.009","volume":"41","author":"Ampe E.","year":"2013","unstructured":"Ampe E.; Delaere B.; Hecq J.D.; Tulkens P.M.; Glupczynski Y.; Implementation of a protocol for administration of vancomycin by continuous infusion: Pharmacokinetic, pharmacodynamic and toxicological aspects. Int J Antimicrob Agents 2013,41(5),439-446","journal-title":"Int J Antimicrob Agents"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1097\/FTD.0000000000000061","volume":"36","author":"Han H.K.","year":"2014","unstructured":"Han H.K.; An H.; Shin K.H.; Trough concentration over 12.1 mg\/L is a major risk factor of vancomycin-related nephrotoxicity in patients with therapeutic drug monitoring. Ther Drug Monit 2014,36(5),606-611","journal-title":"Ther Drug Monit"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1093\/jpids\/piaa078","volume":"9","author":"Burns A.N.","year":"2020","unstructured":"Burns A.N.; Goldman J.L.; A moving target-vancomycin therapeutic monitoring. J Pediatric Infect Dis Soc 2020,9(4),474-478","journal-title":"J Pediatric Infect Dis Soc"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1093\/cid\/ciz051","volume":"69","author":"Aljefri D.M.","year":"2019","unstructured":"Aljefri D.M.; Avedissian S.N.; Rhodes N.J.; Postelnick M.J.; Nguyen K.; Scheetz M.H.; Vancomycin area under the curve and acute kidney injury: A meta-analysis. Clin Infect Dis 2019,69(11),1881-1887","journal-title":"Clin Infect Dis"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"e02042","DOI":"10.1128\/AAC.02042-17","volume":"62","author":"Neely M.N.","year":"2018","unstructured":"Neely M.N.; Kato L.; Youn G.; Prospective trial on the use of trough concentration versus area under the curve to determine therapeutic vancomycin dosing. Antimicrob Agents Chemother 2018,62(2),e02042-e17","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=25","first-page":"1","author":"Lines J.","year":"2020","unstructured":"Lines J.; Burchette J.; Kullab S.M.; Lewis P.; Evaluation of a troughonly extrapolated area under the curve vancomycin dosing method on clinical outcomes. Int J Clin Pharm 2020,1-7","journal-title":"Int J Clin Pharm"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1007\/s13318-019-00551-1","volume":"44","author":"Al-Sulaiti F.K.","year":"2019","unstructured":"Al-Sulaiti F.K.; Nader A.M.; Saad M.O.; Clinical and pharmacokinetic outcomes of peak-trough-based versus trough-based vancomycin therapeutic drug monitoring approaches: A pragmatic randomized controlled trial. Eur J Drug Metab Pharmacokinet 2019,44(5),639-652","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.ijantimicag.2018.12.014","volume":"53","author":"Drennan P.G.","year":"2019","unstructured":"Drennan P.G.; Begg E.J.; Gardiner S.J.; Kirkpatrick C.M.J.; Chambers S.T.; The dosing and monitoring of vancomycin: What is the best way forward? Int J Antimicrob Agents 2019,53(4),401-407","journal-title":"Int J Antimicrob Agents"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1159\/000343162","volume":"58","author":"Suzuki Y.","year":"2012","unstructured":"Suzuki Y.; Kawasaki K.; Sato Y.; Is peak concentration needed in therapeutic drug monitoring of vancomycin? A pharmacokinetic-pharmacodynamic analysis in patients with methicillin-resistant Staphylococcus aureus pneumonia. Chemotherapy 2012,58(4),308-312","journal-title":"Chemotherapy"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"e02490","DOI":"10.1128\/AAC.02490-16","volume":"61","author":"Pai M.P.","year":"2017","unstructured":"Pai M.P.; Hong J.; Krop L.; Peak measurement for vancomycin AUC estimation in obese adults improves precision and lowers bias. Antimicrob Agents Chemother 2017,61(4),e02490-e16","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.cmi.2019.12.023","volume":"26","author":"Holmes N.E.","year":"2020","unstructured":"Holmes N.E.; Using AUC\/MIC to guide vancomycin dosing: Ready for prime time? Clin Microbiol Infect 2020,26(4),406-408","journal-title":"Clin Microbiol Infect"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s40262-012-0020-y","volume":"52","author":"Fuchs A.","year":"2013","unstructured":"Fuchs A.; Csajka C.; Thoma Y.; Buclin T.; Widmer N.; Benchmarking therapeutic drug monitoring software: A review of available computer tools. Clin Pharmacokinet 2013,52(1),9-22","journal-title":"Clin Pharmacokinet"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1002\/phar.2191","volume":"38","author":"Turner R.B.","year":"2018","unstructured":"Turner R.B.; Kojiro K.; Shephard E.A.; Review and validation of bayesian dose\u2010optimizing software and equations for calculation of the vancomycin area under the curve in critically ill patients. Pharmacotherapy. Pharmacotherapy 2018,38(12),1174-1183","journal-title":"Pharmacotherapy"},{"key":"ref=33","author":"Guo T.","year":"2020","unstructured":"Guo T.; Van Hest R.M.; Fleuren L.M.; Roggeveen L.F.; Bosman R.J.; Van der Voort P.H.; Why we should sample sparsely and aim for a higher target: Lessons from model\u2010based therapeutic drug monitoring of vancomycin in intensive care patients. Br J Clin Pharmacol 2020","journal-title":"Br J Clin Pharmacol"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1016\/j.ijantimicag.2018.08.024","volume":"52","author":"Mogle B.T.","year":"2018","unstructured":"Mogle B.T.; Steele J.M.; Seabury R.W.; Dang U.J.; Kufel W.D.; Implementation of a two-point pharmacokinetic AUC-based vancomycin therapeutic drug monitoring approach in patients with methicillin-resistant Staphylococcus aureus bacteraemia. Int J Antimicrob Agents 2018,52(6),805-810","journal-title":"Int J Antimicrob Agents"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"106109","DOI":"10.1016\/j.ijantimicag.2020.106109","volume":"56","author":"Oda K.","year":"2020","unstructured":"Oda K.; Jono H.; Nosaka K.; Saito H.; Reduced nephrotoxicity with vancomycin therapeutic drug monitoring guided by area under the concentration-time curve against a trough 15-20 &#x3BC;g\/mL concentration. Int J Antimicrob Agents 2020,56(4),106109","journal-title":"Int J Antimicrob Agents"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"1986","DOI":"10.2146\/ajhp180034","volume":"75","author":"Heil E.L.","year":"2018","unstructured":"Heil E.L.; Claeys K.C.; Mynatt R.P.; Making the change to area under the curve-based vancomycin dosing. Am J Health Syst Pharm 2018,75(24),1986-1995","journal-title":"Am J Health Syst Pharm"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1373\/jalm.2018.027391","volume":"3","author":"Biagi M.J.","year":"2019","unstructured":"Biagi M.J.; Butler D.A.; Wenzler E.; AUC-based monitoring of vancomycin: Closing the therapeutic window. J Appl Lab Med 2019,3(4),743-746","journal-title":"J Appl Lab Med"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1097\/FTD.0000000000000250","volume":"38","author":"Haeseker M.","year":"2016","unstructured":"Haeseker M.; Croes S.; Neef C.; Bruggeman C.; Stolk L.; Verbon A.; Evaluation of vancomycin prediction methods based on estimated creatinine clearance or trough levels. Ther Drug Monit 2016,38(1),120-126","journal-title":"Ther Drug Monit"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1097\/00007691-199001000-00006","volume":"12","author":"Tan C.C.","year":"1990","unstructured":"Tan C.C.; Lee H.S.; Ti T.Y.; Lee E.J.; Pharmacokinetics of intravenous vancomycin in patients with end-stage renal failure. Ther Drug Monit 1990,12(1),29-34","journal-title":"Ther Drug Monit"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1128\/AAC.25.4.433","volume":"25","author":"Matzke G.R.","year":"1984","unstructured":"Matzke G.R.; McGory R.W.; Halstenson C.E.; Keane W.F.; Pharmacokinetics of vancomycin in patients with various degrees of renal function. Antimicrob Agents Chemother 1984,25(4),433-437","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1038\/clpt.1991.208","volume":"50","author":"Macias W.L.","year":"1991","unstructured":"Macias W.L.; Mueller B.A.; Scarim S.K.; Vancomycin pharmacokinetics in acute renal failure: Preservation of nonrenal clearance. Clin Pharmacol Ther 1991,50(6),688-694","journal-title":"Clin Pharmacol Ther"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1097\/FTD.0000000000000666","volume":"41","author":"Goti V.","year":"2019","unstructured":"Goti V.; Chaturvedula A.; Fossler M.; Hospitalized patients with and without hemodialysis have markedly different vancomycin pharmacokinetics: A population pharmacokinetic model-based analysis. Ther Drug Monit 2019,41(4),549","journal-title":"Ther Drug Monit"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.jcrc.2019.07.008","volume":"54","author":"Charoensareerat T.","year":"2019","unstructured":"Charoensareerat T.; Chaijamorn W.; Boonpeng A.; Srisawat N.; Pummangura C.; Pattharachayakul S.; Optimal vancomycin dosing regimens for critically ill patients with acute kidney injury during continuous renal replacement therapy: A Monte Carlo simulation study. J Crit Care 2019,54,77-82","journal-title":"J Crit Care"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"84","DOI":"10.4103\/1735-5362.251856","volume":"14","author":"Khoei A.","year":"2019","unstructured":"Khoei A.; Soltani R.; Emami J.; Badri S.; Taheri S.; Therapeutic drug monitoring of vancomycin by AUC&#x3C4;-MIC ratio in patients with chronic kidney disease. Res Pharm Sci 2019,14(1),84-92","journal-title":"Res Pharm Sci"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1111\/j.1600-0773.1996.tb00242.x","volume":"79","author":"Mart&#xED; R.","year":"1996","unstructured":"Mart&#xED; R.; Rosell M.; Pou L.; Garc&#xED;a L.; Pascual C.; Influence of biochemical parameters of liver function on vancomycin pharmacokinetics. Pharmacol Toxicol 1996,79(2),55-59","journal-title":"Pharmacol Toxicol"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"46","DOI":"10.2165\/00003088-199324010-00004","volume":"24","author":"Westphal J.F.","year":"1993","unstructured":"Westphal J.F.; Brogard J.M.; Clinical pharmacokinetics of newer antibacterial agents in liver disease. Clin Pharmacokinet 1993,24(1),46-58","journal-title":"Clin Pharmacokinet"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s12941-020-00354-2","volume":"19","author":"Brunetti L.","year":"2020","unstructured":"Brunetti L.; Song J.H.; Suh D.; The risk of vancomycin toxicity in patients with liver impairment. Ann Clin Microbiol Antimicrob 2020,19(1),13","journal-title":"Ann Clin Microbiol Antimicrob"},{"key":"ref=48","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.tacc.2021.05.004","volume":"41","author":"Ghasemiyeh P.","year":"2021","unstructured":"Ghasemiyeh P.; Mohammadi-Samani S.; Firouzabadi N.; Vazin A.; Zand F.; A brief ICU residents\u2019 guide: Pharmacotherapy, pharmacokinetic aspects and dose adjustments in critically ill adult patients admitted to ICU. Trend in Anaest Crit Care 2021,41,11-31","journal-title":"Trend in Anaest Crit Care"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/j.diagmicrobio.2018.06.022","volume":"92","author":"Turner R.B.","year":"2018","unstructured":"Turner R.B.; Kojiro K.; Won R.; Chang E.; Chan D.; Elbarbry F.; Prospective evaluation of vancomycin pharmacokinetics in a heterogeneous critically ill population. Diagn Microbiol Infect Dis 2018,92(4),346-351","journal-title":"Diagn Microbiol Infect Dis"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1007\/s40262-016-0475-3","volume":"56","author":"Radke C.","year":"2017","unstructured":"Radke C.; Horn D.; Lanckohr C.; Development of a physiologically based pharmacokinetic modelling approach to predict the pharmacokinetics of vancomycin in critically ill septic patients. Clin Pharmacokinet 2017,56(7),759-779","journal-title":"Clin Pharmacokinet"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"755","DOI":"10.2165\/00003088-200645080-00001","volume":"45","author":"Roberts J.A.","year":"2006","unstructured":"Roberts J.A.; Lipman J.; Antibacterial dosing in intensive care: Pharmacokinetics, degree of disease and pharmacodynamics of sepsis. Clin Pharmacokinet 2006,45(8),755-773","journal-title":"Clin Pharmacokinet"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1093\/jac\/14.suppl_D.53","volume":"14","author":"Garaud J.J.","year":"1984","unstructured":"Garaud J.J.; Regnier B.; Inglebert F.; Faurisson F.; Bauchet J.; Vachon F.; Vancomycin pharmacokinetics in critically ill patients. J Antimicrob Chemother 1984,14(Suppl. D),53-57","journal-title":"J Antimicrob Chemother"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s13054-019-2311-2","volume":"23","author":"Honore P.M.","year":"2019","unstructured":"Honore P.M.; De Bels D.; Kugener L.; Vancomycin pharmacokinetics in critically ill obese patients: Can the clinician sit back and relax? Crit Care 2019,23(1),15","journal-title":"Crit Care"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/j.burns.2009.08.010","volume":"36","author":"Dolton M.","year":"2010","unstructured":"Dolton M.; Xu H.; Cheong E.; Vancomycin pharmacokinetics in patients with severe burn injuries. Burns 2010,36(4),469-476","journal-title":"Burns"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1128\/AAC.34.5.792","volume":"34","author":"Rybak M.J.","year":"1990","unstructured":"Rybak M.J.; Albrecht L.M.; Berman J.R.; Warbasse L.H.; Svensson C.K.; Vancomycin pharmacokinetics in burn patients and intravenous drug abusers. Antimicrob Agents Chemother 1990,34(5),792-795","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/j.burns.2018.09.025","volume":"45","author":"Hill D.M.","year":"2019","unstructured":"Hill D.M.; Velamuri S.R.; Lanfranco J.; Romero Legro I.; Sinclair S.E.; Hickerson W.L.; Optimization of an empiric vancomycin dosing algorithm for improved target concentration attainment in patients with thermal injury. Burns 2019,45(2),423-432","journal-title":"Burns"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1128\/AAC.34.6.1227","volume":"34","author":"Small P.M.","year":"1990","unstructured":"Small P.M.; Chambers H.F.; Vancomycin for Staphylococcus aureus endocarditis in intravenous drug users. Antimicrob Agents Chemother 1990,34(6),1227-1231","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1097\/01.AOG.0000260388.78339.b6","volume":"109","author":"Laiprasert J.","year":"2007","unstructured":"Laiprasert J.; Klein K.; Mueller B.A.; Pearlman M.D.; Transplacental passage of vancomycin in noninfected term pregnant women. Obstet Gynecol 2007,109(5),1105-1110","journal-title":"Obstet Gynecol"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1016\/0002-9378(89)90766-7","volume":"161","author":"Reyes M.P.","year":"1989","unstructured":"Reyes M.P.; Ostrea E.M.; Cabinian A.E.; Schmitt C.; Rintelmann W.; Vancomycin during pregnancy: does it cause hearing loss or nephrotoxicity in the infant? Am J Obstet Gynecol 1989,161(4),977-981","journal-title":"Am J Obstet Gynecol"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1002\/phar.1321","volume":"33","author":"Heble D.E.","year":"2013","unstructured":"Heble D.E.; McPherson C.; Nelson M.P.; Hunstad D.A.; Vancomycin trough concentrations in overweight or obese pediatric patients. Pharmacotherapy 2013,33(12),1273-1277","journal-title":"Pharmacotherapy"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1177\/089033440001600413","volume":"16","author":"Chin K.G.","year":"2000","unstructured":"Chin K.G.; Mactal-Haaf C.; McPherson C.E.; Use of anti-infective agents during lactation: Part 1-Beta-lactam antibiotics, vancomycin, quinupristin-dalfopristin, and linezolid. J Hum Lact 2000,16(4),351-358","journal-title":"J Hum Lact"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"1179548420930925","DOI":"10.1177\/1179548420930925","volume":"14","author":"White S.","year":"2020","unstructured":"White S.; Sakon C.; Fitzgerald L.; Kam C.; McDade E.; Wong A.; Comparison of vancomycin pharmacokinetics in cystic fibrosis patients pre and post-lung transplant. Clin Med Insights Circ Respir Pulm Med 2020,14,1179548420930925","journal-title":"Clin Med Insights Circ Respir Pulm Med"},{"key":"ref=63","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1007\/s12630-018-1201-4","volume":"65","author":"Tsang M.","year":"2018","unstructured":"Tsang M.; A practice of aesthesia for infants and children. Can J Anest 2018,65(12),1392-1393","journal-title":"Can J Anest"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1186\/s12879-020-05067-7","volume":"20","author":"Pan Y.","year":"2020","unstructured":"Pan Y.; He X.; Yao X.; The effect of body mass index and creatinine clearance on serum trough concentration of vancomycin in adult patients. BMC Infect Dis 2020,20(1),341","journal-title":"BMC Infect Dis"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1128\/AAC.37.3.436","volume":"37","author":"Vance-Bryan K.","year":"1993","unstructured":"Vance-Bryan K.; Guay D.R.; Gilliland S.S.; Rodvold K.A.; Rotschafer J.C.; Effect of obesity on vancomycin pharmacokinetic parameters as determined by using a Bayesian forecasting technique. Antimicrob Agents Chemother 1993,37(3),436-440","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/j.amjmed.2008.01.046","volume":"121","author":"Hall R.G.","year":"2008","unstructured":"Hall R.G.; Payne K.D.; Bain A.M.; Multicenter evaluation of vancomycin dosing: emphasis on obesity. Am J Med 2008,121(6),515-518","journal-title":"Am J Med"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1111\/bcp.14144","volume":"86","author":"Smit C.","year":"2020","unstructured":"Smit C.; Wasmann R.E.; Goulooze S.C.; Population pharmacokinetics of vancomycin in obesity: Finding the optimal dose for (morbidly) obese individuals. Br J Clin Pharmacol 2020,86(2),303-317","journal-title":"Br J Clin Pharmacol"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1093\/jac\/dks066","volume":"67","author":"Grace E.","year":"2012","unstructured":"Grace E.; Altered vancomycin pharmacokinetics in obese and morbidly obese patients: what we have learned over the past 30 years. J Antimicrob Chemother 2012,67(6),1305-1310","journal-title":"J Antimicrob Chemother"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1002\/phar.2367","volume":"40","author":"Masich A.M.","year":"2020","unstructured":"Masich A.M.; Kalaria S.N.; Gonzales J.P.; Vancomycin pharmacokinetics in obese patients with sepsis or septic shock. Pharmacotherapy 2020,40(3),211-220","journal-title":"Pharmacotherapy"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1248\/bpb.32.99","volume":"32","author":"Omote S.","year":"2009","unstructured":"Omote S.; Yano Y.; Hashida T.; A retrospective analysis of vancomycin pharmacokinetics in Japanese cancer and non-cancer patients based on routine trough monitoring data. Biol Pharm Bull 2009,32(1),99-104","journal-title":"Biol Pharm Bull"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1177\/1078155209355847","volume":"16","author":"Al-Kofide H.","year":"2010","unstructured":"Al-Kofide H.; Zaghloul I.; Al-Naim L.; Pharmacokinetics of vancomycin in adult cancer patients. J Oncol Pharm Pract 2010,16(4),245-250","journal-title":"J Oncol Pharm Pract"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.jiac.2019.12.019","volume":"26","author":"Zhang X.","year":"2020","unstructured":"Zhang X.; Wang D.; The characteristics and impact indicator of vancomycin pharmacokinetics in cancer patients complicated with severe pneumonia. J Infect Chemother 2020,26(5),492-497","journal-title":"J Infect Chemother"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1248\/bpb.b20-00083","volume":"43","author":"Izumisawa T.","year":"2020","unstructured":"Izumisawa T.; Wakui N.; Kaneko T.; Increased vancomycin clearance in patients with solid malignancies. Biol Pharm Bull 2020,43(7),1081-1087","journal-title":"Biol Pharm Bull"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1007\/s13318-019-00564-w","volume":"44","author":"Nakayama H.","year":"2019","unstructured":"Nakayama H.; Suzuki M.; Kato T.; Echizen H.; Vancomycin pharmacokinetics in patients with advanced cancer near end of life. Eur J Drug Metab Pharmacokinet 2019,44(6),837-843","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"s82","DOI":"10.1590\/1806-9282.66.s1.82","volume":"66","author":"Sales G.T.M.","year":"2020","unstructured":"Sales G.T.M.; Foresto R.D.; Drug-induced nephrotoxicity. Rev Assoc Med Bras 2020,66(66)(Suppl. 1),s82-s90","journal-title":"Rev Assoc Med Bras"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"20681","DOI":"10.1038\/s41598-021-00214-9","volume":"11","author":"Kwak S.","year":"2021","unstructured":"Kwak S.; Kim J.Y.; Cho H.; Vancomycin-induced nephrotoxicity in non-intensive care unit pediatric patients. Sci Rep 2021,11(1),20681","journal-title":"Sci Rep"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.2147\/IDR.S171669","volume":"11","author":"Barcel&#xF3;-Vidal J.","year":"2018","unstructured":"Barcel&#xF3;-Vidal J.; Rodr&#xED;guez-Garc&#xED;a E.; Grau S.; Extremely high levels of vancomycin can cause severe renal toxicity. Infect Drug Resist 2018,11,1027-1030","journal-title":"Infect Drug Resist"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1186\/s40064-015-1146-9","volume":"4","author":"Cardile A.P.","year":"2015","unstructured":"Cardile A.P.; Tan C.; Lustik M.B.; Optimization of time to initial vancomycin target trough improves clinical outcomes. Springerplus 2015,4(1),364","journal-title":"Springerplus"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"595","DOI":"10.2147\/TCRM.S259152","volume":"16","author":"Ghasemiyeh P.","year":"2020","unstructured":"Ghasemiyeh P.; Borhani-Haghighi A.; Karimzadeh I.; Major neurologic adverse drug reactions, potential drug-drug interactions and pharmacokinetic aspects of drugs used in COVID-19 patients with stroke: A narrative review. Ther Clin Risk Manag 2020,16,595-605","journal-title":"Ther Clin Risk Manag"},{"key":"ref=80","first-page":"65","volume":"6","author":"Ghasemiyeh P.","year":"2020","unstructured":"Ghasemiyeh P.; Mohammadi-Samani S.; Iron chelating agents: Promising supportive therapies in severe cases of COVID-19? Trends Pharmacol Sci 2020,6(2),65-66","journal-title":"Trends Pharmacol Sci"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1016\/j.hrtlng.2020.08.025","volume":"49","author":"Ghasemiyeh P.","year":"2020","unstructured":"Ghasemiyeh P.; Mohammadi-Samani S.; COVID-19 outbreak: Challenges in pharmacotherapy based on pharmacokinetic and pharmacodynamic aspects of drug therapy in patients with moderate to severe infection. Heart Lung 2020,49(6),763-773","journal-title":"Heart Lung"},{"key":"ref=82","first-page":"153","volume":"7","author":"Ghasemiyeh P.","year":"2021","unstructured":"Ghasemiyeh P.; Mohammadi-Samani S.; Vazin A.; Micronutrients supplementation in pregnant women during COVID-19 pan-demy: Pros and cons. Trends Pharmacol Sci 2021,7(3),153-160","journal-title":"Trends Pharmacol Sci"},{"key":"ref=83","first-page":"e2021250","volume":"92","author":"Ghasemiyeh P.","year":"2021","unstructured":"Ghasemiyeh P.; Mohammadi-Samani S.; The necessity of early anti-inflammatory therapy initiation in cases with mild-to-moderate COVID-19: A personal experience from an attending pharmacist and his resident. Acta Bio-med. Atenei Parmensis 2021,92(3),e2021250","journal-title":"Atenei Parmensis"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"108162","DOI":"10.1016\/j.intimp.2021.108162","volume":"100","author":"Ghasemiyeh P.","year":"2021","unstructured":"Ghasemiyeh P.; Mohammadi-Samani S.; Firouzabadi N.; Dehshahri A.; Vazin A.; A focused review on technologies, mechanisms, safety, and efficacy of available COVID-19 vaccines. Int Immunopharmacol 2021,100,108162","journal-title":"Int Immunopharmacol"},{"key":"ref=85","first-page":"66","volume":"20","author":"Ghasemiyeh P.","year":"2021","unstructured":"Ghasemiyeh P.; Mortazavi N.; Karimzadeh I.; Psychiatric adverse drug reactions and potential anti-COVID-19 drug interactions with psychotropic medications. Iran J Pharm Res 2021,20(3),66-77","journal-title":"Iran J Pharm Res"},{"key":"ref=86","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.2217\/fmb-2021-0116","volume":"16","author":"Zarkesh K.","year":"2021","unstructured":"Zarkesh K.; Entezar-Almahdi E.; Ghasemiyeh P.; Drug-based therapeutic strategies for COVID-19-infected patients and their challenges. Future Microbiol 2021,16(18),1415-1451","journal-title":"Future Microbiol"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/S0009-9236(96)90060-0","volume":"60","author":"Fern&#xE1;ndez de Gatta M.D.","year":"1996","unstructured":"Fern&#xE1;ndez de Gatta M.D.; Calvo M.V.; Hern&#xE1;ndez J.M.; Caballero D.; San Miguel J.F.; Dom&#xED;nguez-Gil A.; Cost-effectiveness analysis of serum vancomycin concentration monitoring in patients with hematologic malignancies. Clin Pharmacol Ther 1996,60(3),332-340","journal-title":"Clin Pharmacol Ther"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"163","DOI":"10.3390\/jpm12020163","volume":"12","author":"Kim Y.","year":"2022","unstructured":"Kim Y.; Kim S.; Park J.; Lee H.; Clinical response and hospital costs of therapeutic drug monitoring for vancomycin in elderly patients. J Pers Med 2022,12(2),163","journal-title":"J Pers Med"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.2146\/ajhp040555","volume":"62","author":"Bond C.A.","year":"2005","unstructured":"Bond C.A.; Raehl C.L.; Clinical and economic outcomes of pharmacist-managed aminoglycoside or vancomycin therapy. Am J Health Syst Pharm 2005,62(15),1596-1605","journal-title":"Am J Health Syst Pharm"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1093\/jpids\/piaa057","volume":"9","author":"Rybak M.J.","year":"2020","unstructured":"Rybak M.J.; Le J.; Lodise T.; Executive summary: Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: A revised consensus guideline and review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. J Pediatric Infect Dis Soc 2020,9(3),281-284","journal-title":"J Pediatric Infect Dis Soc"}],"container-title":["Current Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1574886317666220801124718","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/207170\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1574886317666220801124718","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,6]],"date-time":"2023-08-06T12:08:33Z","timestamp":1691323713000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/207170\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":90,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1574886317666220801124718","relation":{},"ISSN":["1574-8863"],"issn-type":[{"value":"1574-8863","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2022-04-05","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-05-22","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-05-26","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-04-27","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}